Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Tyvaso Dpi Generic Name & Formulations
Legal Class
Rx
General Description
Treprostinil 16mcg, 32mcg, 48mcg, 64mcg; per cartridge; dry pwd for inh.
Pharmacological Class
Prostacyclin analogue.
See Also
How Supplied
Ampules (2.9mL)—4; Starter Kit—1 (28 ampules with inhalation system); Refill Kit—1 (28 ampules with accessories); DPI Titration Kit—1 (112 cartridges [16mcg] + 84 cartridges [32mcg] w. 5 inhalers); (112 cartridges [16mcg] + 112 cartridges [32mcg] + 28 cartridges [48mcg] w. 5 inhalers); DPI Maintenance Kit—1 (112 cartridges [16mcg, 32mcg, 48mcg, or 64mcg] w. 5 inhalers); (112 cartridges [32mcg] + 112 cartridges [48mcg] w. 5 inhalers)
Manufacturer
Generic Availability
NO
Mechanism of Action
Treprostinil, a prostacyclin analogue, directly vasodilates pulmonary and systemic arterial vascular beds and inhibits platelet aggregation.
Tyvaso Dpi Indications
Indications
To improve exercise ability in patients with: pulmonary arterial hypertension (WHO Group 1) with NYHA Class III symptoms; and pulmonary hypertension associated with interstitial lung disease (WHO Group 3).
Tyvaso Dpi Dosage and Administration
Adult
Give 4 separate, equally spaced treatment sessions each day approximately 4hrs apart, during waking hours. ≥18yrs: Initially 16mcg per treatment session. Maintenance: increase by 16mcg per session at approximately 1–2 week intervals; target dose usually: 48–64mcg per session. Dosage for transition from Tyvaso Inhalation Solution: see full labeling.
Children
<18yrs: not established.
Tyvaso Dpi Contraindications
Not Applicable
Tyvaso Dpi Boxed Warnings
Not Applicable
Tyvaso Dpi Warnings/Precautions
Warnings/Precautions
Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly. Risk of bleeding. Asthma, COPD, or other bronchial hyperreactivity. For Tyvaso Inhalation Solution: avoid contact with eyes and skin, oral ingestion. Elderly. Pregnancy. Nursing mothers.
Tyvaso Dpi Pharmacokinetics
Elimination
Renal (79%), fecal (13%). Half-life: ~4 hours (Tyvaso Inhalation Solution); 27–50 minutes (Tyvaso DPI).
Tyvaso Dpi Interactions
Interactions
Do not use with other medications. May be potentiated by CYP2C8 inhibitor (eg, gemfibrozil). May be antagonized by CYP2C8 inducer (eg, rifampin).
Tyvaso Dpi Adverse Reactions
Adverse Reactions
Cough, headache, nausea, diarrhea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, syncope, dyspnea; symptomatic hypotension, bleeding, bronchospasm.
Tyvaso Dpi Clinical Trials
See Literature
Tyvaso Dpi Note
Not Applicable
Tyvaso Dpi Patient Counseling
See Literature
